bringing vaccines to patients is a lengthy process. Clinical trials take a big part of it. Vaccines which are licensed have not only proven safety and efficacy in clinical trials, they also generate important data on immune proflling, like antibodies and cellular immunity which are in correlation with protection. In almost all cases, one or two vaccines are not enough to cover the needs of everybody everywhere. If we find a way that newcomers can proof that they develop the same or similar amount of antibodies and/or cellular immunity as the already approved vaccine(s), the clinical trials can by shortened tremendously and access to vaccines increased for all with numbers of years. IABS is working on this.

Actors4Health facilitates the creation of a regulatory framework that enables the use of the technology platform approach. Allowing quicker vaccine development. If a vaccine is licensed based on one technology platform, mRNA for example, the same platform can be used to develop a vaccine against other diseases. In that case, these “follower” vaccines can use the common parts of the file without being obliged to redo all the trials. This represents a gain of time and investment to increase access to vaccines for pandemics and diseases for which no vaccine exists today.

The quality of vaccines is tested against validated standards to assure that vaccines reach at least the quality of well-known standards. The production and availability of widely accepted standards is a key factor for global access to quality vaccines. We promote and support the establishment of such standards to not only assure access to vaccines but also guarantee their quality everywhere.

Since decades, vaccines are released to the market after safety and efficacy testing in animals. These animal tests are costly, lengthy, moderately, and badly reliable and pose a huge burden on animal welfare. In many cases these animal tests can be replaced by in vitro laboratory tests which are much more precise and reliable, short in time and less costly shorting time for access to vaccines and antibodies and increasing global access.

As in the case for Standards, there is a large array of specifications in vaccine, antibody and cell production that must be complied with to assure the quality of the products. Understanding and complying with the specifications assures robust production processes, high quality and increased access and comparable quality everywhere.

Allows to guarantee the quality attributes of biologicals and their purity in a very short time with the highest precision. It allows further reduction of the use of laboratory animals. NGS increase speed of quality assurance and by this way access for all to high quality vaccines, antibodies and cell therapies.

l’innovation permet de développer des vaccins et autres produits biologiques contre des maladies qui étaient encore totalement mortelles il y a une dizaine d’années: sans nouvelles plateformes technologiques, pas de nouveaux vaccins contre le COVID, RSV (bronchiolite des enfants) et autant d’autres à venir tels les progrès importants dans le domaine de l’immunothérapie et la thérapie cellulaire des cancers. Notre première priorité est l’innovation : anticiper l’impact des nouvelles technologies et assurer leur accès partout à tous les patients.

Actors4Health is active in supporting cell and gene therapy developments and regulatory processes so that they profit to cancer patients.

Animals can be victim of infectious diseases for which no cure nor vaccine exists. In some cases, the solution exists in isolating the germ causing the disease in the farm and make a vaccine out of it for use in the farm. Very often this leads to the solution of the disease problem. We promote the establishment of rules on safety and efficacy specifically adapted to this kind of vaccines.